{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:45:11Z","timestamp":1774485911043,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.advms.2013.11.001","type":"journal-article","created":{"date-parts":[[2014,3,22]],"date-time":"2014-03-22T20:52:39Z","timestamp":1395521559000},"page":"1-6","source":"Crossref","is-referenced-by-count":37,"title":["Anorexia\u2013cachexia syndrome in pancreatic cancer: Recent advances and new pharmacological approach"],"prefix":"10.1016","volume":"59","author":[{"given":"Ilaria","family":"Ronga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Gallucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinando","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Generoso","family":"Uomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.advms.2013.11.001_bib0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/1471-2407-12-265","article-title":"Real-imaging cDNA-AFLP transcript profiling of pancreatic cancer patients: Egr-1 as a potential key regulator of muscle cachexia","volume":"12","author":"Skorokhod","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.advms.2013.11.001_bib0010","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrgastro.2010.61","article-title":"Chemoprevention strategies for pancreatic cancer","volume":"7","author":"Stan","year":"2010","journal-title":"Nat Rev Gatroenteral Hepatol"},{"key":"10.1016\/j.advms.2013.11.001_bib0015","first-page":"465","article-title":"Surgical options in the management of pancreatic cancer","volume":"64","author":"Hackert","year":"2009","journal-title":"Minerva Chir"},{"key":"10.1016\/j.advms.2013.11.001_bib0020","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.soc.2004.04.004","article-title":"Palliative therapy for pancreatic\/biliary cancer","volume":"13","author":"House","year":"2004","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.advms.2013.11.001_bib0025","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s11605-011-1665-9","article-title":"Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience","volume":"15","author":"Kneuertz","year":"2011","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.advms.2013.11.001_bib0030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/1471-2407-9-255","article-title":"Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function","volume":"9","author":"Bachmann","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.advms.2013.11.001_bib0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/01635589809514717","article-title":"Prognosis of advanced pancreatic cancer patients with reference to calorie intake","volume":"32","author":"Okusaka","year":"1998","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.advms.2013.11.001_bib0040","first-page":"240","article-title":"Supportive and Palliative care of Pancreatic cancer","volume":"10","author":"Fazal","year":"2007","journal-title":"JOP"},{"key":"10.1016\/j.advms.2013.11.001_bib0045","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.advms.2013.11.001_bib0050","first-page":"157","article-title":"Anorexia\u2013Cachexia Syndrome in pancreatic cancer: recent development in research and management","volume":"7","author":"Uomo","year":"2006","journal-title":"JOP"},{"key":"10.1016\/j.advms.2013.11.001_bib0055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3322\/canjclin.52.2.72","article-title":"Cancer anorexia\u2013cachexia syndrome: current issues in research and management","volume":"52","author":"Inui","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.advms.2013.11.001_bib0060","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nrc927","article-title":"Cachexia in cancer patients","volume":"2","author":"Tisdale","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.advms.2013.11.001_bib0065","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1200\/JCO.1994.12.1.213","article-title":"The cancer anorexia\u2013cachexia syndrome","volume":"12","author":"Nelson","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2013.11.001_bib0070","doi-asserted-by":"crossref","first-page":"154","DOI":"10.7762\/cnr.2013.2.2.154","article-title":"Changes in dietary intake, body weight, nutritional status, and metabolic rate in a pancreatic cancer patient","volume":"2","author":"Kim","year":"2013","journal-title":"Clin Nutr Res"},{"key":"10.1016\/j.advms.2013.11.001_bib0075","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.biocel.2013.05.032","article-title":"Muscle wasting in cancer","volume":"45","author":"Johns","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.advms.2013.11.001_bib0080","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/ajcn\/83.6.1345","article-title":"Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis","volume":"83","author":"Fearon","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.advms.2013.11.001_bib0085","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","article-title":"Mechanism of cancer cachexia","volume":"89","author":"Tisdale","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1016\/j.advms.2013.11.001_bib0090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1072-7515(03)00382-X","article-title":"Understanding and managing cancer cachexia","volume":"197","author":"MacDonald","year":"2003","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.advms.2013.11.001_bib0095","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin Nutr"},{"key":"10.1016\/j.advms.2013.11.001_bib0100","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.2174\/138161212803216889","article-title":"Cachexia and oxidative stress in cancer: an innovative therapeutic management","volume":"18","author":"Mantovani","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.advms.2013.11.001_bib0105","doi-asserted-by":"crossref","first-page":"601434","DOI":"10.1155\/2011\/601434","article-title":"Cancer cachexia: mechanisms and clinical implications","volume":"2011","author":"Donohoe","year":"2011","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.advms.2013.11.001_bib0110","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2036.2005.02628.x","article-title":"Review article: anorexia and cachexia in gastrointestinal cancer","volume":"22","author":"Ockenga","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.advms.2013.11.001_bib0115","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/MAJ.0b013e31821cc47f","article-title":"Dietary and pharmacological management of severe catabolic conditions","volume":"342","author":"Elamin","year":"2011","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.advms.2013.11.001_bib0120","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/01.mco.0000134363.53782.cb","article-title":"Cancer anorexia\u2013cachexia syndrome: cytokines and neuropeptides","volume":"7","author":"Ramos","year":"2004","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.advms.2013.11.001_bib0125","first-page":"4493","article-title":"Cancer anorexia\u2013cachexia syndrome: are neuropeptides the key?","volume":"59","author":"Inui","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.advms.2013.11.001_bib0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0889-8588(01)00006-5","article-title":"Supportive care for patients with pancreatic adenocarcinoma: symptom control and nutrition","volume":"16","author":"Ellison","year":"2002","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.advms.2013.11.001_bib0135","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.bjc.6600086","article-title":"Role of \u03b2-3 adrenergic receptors in the action of tumour lipid mobilizing factor","volume":"86","author":"Russell","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.advms.2013.11.001_bib0140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2168.2000.01317.x","article-title":"Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor","volume":"87","author":"Wigmore","year":"2000","journal-title":"Br J Surg"},{"key":"10.1016\/j.advms.2013.11.001_bib0145","series-title":"Pancreatic cancer","author":"L\u00f6hr","year":"2005"},{"key":"10.1016\/j.advms.2013.11.001_bib0150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/B978-0-12-410473-0.00011-8","article-title":"Mechanism-based therapeutic approaches to cachexia","volume":"92","author":"Penna","year":"2013","journal-title":"Vitam Horm"},{"key":"10.1016\/j.advms.2013.11.001_bib0155","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1634\/theoncologist.8-1-18","article-title":"Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care","volume":"8","author":"El-Kamar","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.advms.2013.11.001_bib0160","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jpainsymman.2003.09.007","article-title":"Systematic review of megestrol acetate in the treatment of anorexia\u2013cachexia syndrome","volume":"27","author":"Pascual L\u00f3pez","year":"2004","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.advms.2013.11.001_bib0165","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004310.pub3","article-title":"Megestrol acetate for treatment of anorexia cachexia syndrome","author":"Ruiz Garcia","year":"2013","journal-title":"CDS Rev"},{"key":"10.1016\/j.advms.2013.11.001_bib0170","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s00535-013-0787-0","article-title":"Cancer cachexia \u2013 pathophysiology and management","volume":"48","author":"Suzuki","year":"2013","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.advms.2013.11.001_bib0175","series-title":"John M. Appetite stimulants. Pharmacotherapy of cachexia","first-page":"291","year":"2006"},{"key":"10.1016\/j.advms.2013.11.001_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2013.07.015","article-title":"Clinical evaluation and optimal management of cancer cachexia","author":"Tuca","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.advms.2013.11.001_bib0185","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1200\/JCO.1999.17.10.3299","article-title":"Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia\/cachexia","volume":"17","author":"Loprinzi","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.advms.2013.11.001_bib0190","first-page":"499","article-title":"Pharmacologic therapy for the cancer cachexia\/weight loss syndrome: a data-driven, practical approach","volume":"4","author":"Jatoi","year":"2006","journal-title":"J Support Oncol"},{"key":"10.1016\/j.advms.2013.11.001_bib0195","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2165\/00003495-200161040-00004","article-title":"Managing cancer-related anorexia\/cachexia","volume":"61","author":"Mantovani","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.advms.2013.11.001_bib0200","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/1097-0142(19900615)65:12<2657::AID-CNCR2820651210>3.0.CO;2-S","article-title":"A controlled trial of cyproheptadine in cancer patients with anorexia and\/or cachexia","volume":"65","author":"Kardinal","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.advms.2013.11.001_bib0205","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/104454604773840508","article-title":"A chart review of cyproheptadine for stimulant-induced weight loss","volume":"14","author":"Daviss","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.advms.2013.11.001_bib0210","first-page":"279","article-title":"Effects of cyproheptadine clorhydrate, a serotonin receptor antagonist, on endocrine parameters in weight-loss related amenorrhea","volume":"15","author":"Genazzani","year":"2001","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.advms.2013.11.001_bib0215","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.bjc.6690654","article-title":"The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer","volume":"81","author":"Barber","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.advms.2013.11.001_bib0220","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1207\/S15327914NC3602_6","article-title":"Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer","volume":"36","author":"Wigmore","year":"2000","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.advms.2013.11.001_bib0225","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004597.pub2","article-title":"Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia","author":"Dewey","year":"2007","journal-title":"CDS Rev"},{"key":"10.1016\/j.advms.2013.11.001_bib0230","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/gut.2004.047563","article-title":"Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial","volume":"54","author":"Gordon","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.advms.2013.11.001_bib0235","series-title":"ASCO Gastrointestinal Cancers Symposium","article-title":"Thalidomide versus thalidomide with olanzapine and megastrol acetate in treatment of cachexia in gastrointestinal cancer: a randomized trial","author":"Sanchetee","year":"2010"},{"key":"10.1016\/j.advms.2013.11.001_bib0240","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.nut.2009.07.003","article-title":"Update on melanocortin interventions for cachexia: progress toward clinical application","volume":"26","author":"DeBoer","year":"2010","journal-title":"Nutrition"},{"key":"10.1016\/j.advms.2013.11.001_bib0245","first-page":"1432","article-title":"Role of the central melanocortin system in cachexia","volume":"61","author":"Marks","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.advms.2013.11.001_bib0250","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/en.2005-0142","article-title":"The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist","volume":"146","author":"Markison","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.advms.2013.11.001_bib0255","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.advms.2013.11.001_bib0260","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/35086018","article-title":"Ghrelin: an orexigenic and somatotrophic signal from the stomach","volume":"2","author":"Inui","year":"2001","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.advms.2013.11.001_bib0265","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13539-010-0011-5","article-title":"Ghrelin for cachexia","volume":"1","author":"Akamizu","year":"2010","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.advms.2013.11.001_bib0270","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1053\/j.gastro.2006.01.041","article-title":"Therapeutic action of ghrelin in a mouse model of colitis","volume":"130","author":"Gonzalez-Rey","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.advms.2013.11.001_bib0275","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.surg.2007.09.039","article-title":"Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways","volume":"143","author":"Waseem","year":"2008","journal-title":"Surgery"},{"key":"10.1016\/j.advms.2013.11.001_bib0280","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1172\/JCI200421134","article-title":"Ghrelin inhibits leptin- and activation induced proinflammatory cytokine expression by human monocytes and T cells","volume":"114","author":"Dixit","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.advms.2013.11.001_bib0285","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1161\/01.CIR.0000127956.43874.F2","article-title":"Ghrelin inhibits proinflammatory responses and nuclear factor-kB activation in human endothelial cells","volume":"109","author":"Li","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.advms.2013.11.001_bib0290","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1164\/rccm.200604-511OC","article-title":"Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats","volume":"176","author":"Wu","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.advms.2013.11.001_bib0295","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.4049\/jimmunol.0803362","article-title":"Suppression of experimental autoimmune encephalomyelitis by ghrelin","volume":"183","author":"Theil","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.advms.2013.11.001_bib0300","series-title":"J Clin Oncol, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol. 25, no. 18S (June 20 Supplement)","first-page":"9133","article-title":"A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia","author":"Garcia","year":"2007"},{"key":"10.1016\/j.advms.2013.11.001_bib0305","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00520-012-1500-1","article-title":"Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study","volume":"21","author":"Garcia","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.advms.2013.11.001_bib0310","first-page":"445","article-title":"Cancer cachexia: pathophysiologic aspects and treatment options","volume":"8","author":"Topkan","year":"2007","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.advms.2013.11.001_bib0315","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1634\/theoncologist.2009-0153","article-title":"Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia","volume":"15","author":"Mantovani","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.advms.2013.11.001_bib0320","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/0973-1075.73644","article-title":"Treatment of cachexia in oncology","volume":"16","author":"Tazi","year":"2010","journal-title":"Indian J Palliat Care"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112614000066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112614000066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T20:34:14Z","timestamp":1565296454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112614000066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1896112614000066"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2013.11.001","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}